Canada Markets close in 6 hrs 28 mins

Alpha Cognition Inc. (ACOGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.6106-0.0394 (-6.06%)
As of 10:44AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.6500
Open0.6106
BidN/A x N/A
AskN/A x N/A
Day's Range0.6106 - 0.6106
52 Week Range0.4880 - 1.8000
Volume525
Avg. Volume5,356
Market Cap38.486M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3780
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.75
  • Business Wire

    Alpha Cognition Announces Fourth Quarter and Full Year 2021 Results and Company Update

    VANCOUVER, April 28, 2022--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021.

  • Business Wire

    Alpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of Directors

    VANCOUVER, British Columbia, April 12, 2022--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces the appointment of Don Kalkofen as Chief Financial Officer (CFO) to replace Jeremy Wright. Mr. Wright will continue to assist the Company in a consulting capacity.

  • Business Wire

    Alpha Cognition Announces Positive Data from Pre-Clinical Studies of ALPHA-0602 (Progranulin) for Amyotrophic Lateral Sclerosis (ALS)

    VANCOUVER, British Columbia, March 29, 2022--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce positive preclinical data from their ALPHA-0602 ALS gene therapy program. These data underscore the robust preclinical evidence supporting Alpha Cognition’s AAV-based gen